| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c90c49b7ba36e7dcb625797ab2b01906
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c38615966e4d36f4310f9b1c6e3e1ea8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58987629b3d8dbcc4b6120918be03177 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-21001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2004-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19d60192d81e60193c89b07f8336e17b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ded2c5c27cd3a91ca70c4a1a636c56b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e60f0824ac81970f94d2b4ed3e1943d |
| publicationDate |
2005-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005004903-A1 |
| titleOfInvention |
Method for treating oncological diseases |
| abstract |
The invention relates to medicine and veterinary science and can be used for treating mainly solid tumors. The inventive method for treating oncological diseases consisting in injecting a blood extracellular DNA destroying agent into a systemic blood circulation. Said blood extracellular DNA destroying agent can be embodied in the form of a DNAse enzyme, in particular a bovine pancreatic DNAse which is parenterally injected in doses ranging from of 50 000 Kunz units to 250 000 000 Kunz units a day every day during 5-360 days or in the form of a recombinant human DNAse. In addition, a blood extracellular DNA binding agent embodied in the form of anti-DNA antibodies can be injected into a systemic blood circulation. In addition a modified agent which modifies the chemical composition and/or conformation and/or polymery and/or an association with proteins and/or lipids and/or ribonucleic acids of the blood extracellular DNA. Said modifying agent can be embodied in the form of a enzyme-ribonuclease. An extracellular ribonuclease of a Serratia Mercenses bacterium can be used in the form of said agents. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10617743-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8871200-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8388951-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1880733-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022246139-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8431123-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11701410-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1880733-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8710012-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8796004-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9248166-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9845461-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9463223-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8916151-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8679456-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9072733-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8535663-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9770492-B2 |
| priorityDate |
2003-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |